An investigational Janus kinase 1 (JAK1) preferential inhibitor reduced the risk of treatment failure among patients with active noninfectious uveitis, the phase II randomized HUMBOLDT trial showed.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback